Business Wire

HAI-ROBOTICS

Share
HAI ROBOTICS to Show Its Tallest Robot for the 1st Time in Europe at LogiMAT 2022

HAI ROBOTICS, the pioneer in Autonomous Case-handling Robot (ACR) systems for warehouse logistics, will exhibit its cutting-edge automation technology at LogiMAT 2022, Europe's biggest annual intralogistics tradeshow, from May 31 to June 2 in Stuttgart, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220522005089/en/

The company will show how the ACR systems, a highly flexible goods-to-person solution that improves operation efficiency and storage density, could meet the current needs of Europe's warehouses and distribution centers.

The live demo at Booth D71, Hall 3 will be led by HAIPICK A42T, the tallest robot in HAI ROBOTICS' ACR systems that can reach a max picking height of 10-meters. Featuring a telescopic lift, the robot can also descend to as low as 0.28m to pick totes and cartons stored on the bottom level of the shelf. It can carry 8 loads to feed HAIPORT, goods-to-person workstation, in one move. The robot has been titled the "Best in Intralogistics" in IFOY 2021.

HAIPORT, also to be displayed at LogiMAT, is another warehousing efficiency and throughput booster. With the ability to load four to eight cases in only three seconds from a robot, and unload the same number of cases in five seconds at the same time, a single workstation is able to handle up to 900 cases per hour, an order-fulfillment speed that is 16 times faster than robot-to-conveyor belt transport.

ACR systems, "much more attractive"

HAI ROBOTICS sees the ACR systems a good fit for European users, especially in the age of e-commerce when more consumers are longing for faster deliveries and omni-channel shopping experience.

Mr Kai Ramadhin, the company's VP of Sales & Marketing Europe, said: "HAI ROBOTICS solution provides more flexibility in terms of expansion ability, rapid deployment times and so on. So the sweet-spot of our solution is much more attractive."

Mr Ramadhin noted the company is focused on creating a local network of system integrator, installation and service partners, so that any user of ACR systems can expect rapid and high-quality service wherever they are in Europe.

Since setting up its regional headquarters in the Netherlands in late 2021, HAI ROBOTICS has built a strong localized network in countries of France, Germany, Spain, Italy, the Benelux and the U.K.

The ACR systems are presented by its global partner Savoye at Log!Ville in Belgium in an initiative to make the high-density warehousing technology widely known to the European supply chain. The company has also teamed up with U.K.-based Invar System and Greece's Voyatzoglou Systems to enable tailored service accessible to regional business operators.

When the market gets increasingly dynamic and volatile, the company sees the systems can bring users some key benefits, including:

1. Alleviating labor challenges

Through the automation of practices, warehouses can meet the demands of the modern world by improving employee productivity and filling job vacancies, when recruiting and retaining gets tough.

Robots also free workers from doing repetitive and labour intensive work in the warehouse. The ACR systems, for example, save a worker 40,000 to 60,000 steps of walking per day, on average, according to the company's statistics.

2. Storage space utilization to save land investment

As warehouse ceiling heights have continuously risen, the ACR systems, with the max picking height reaching 10 meters, allow the warehouse to easily use the upper storage space. That may also save the user investment in warehouse expansion, in particular in countries where land costs are high.

3. Fast & flexible implementation, more affordable

Business owners are facing a fast-changing and less predictable market nowadays than ever before. The growing customer expectations for faster deliveries and omni-channel shopping experience are driving companies to rethink their supply-chain operating models. The ACR systems have the high level of flexibility to allow a project to be deployed within months, and can be easily scaled according to business volume. A warehouse owner can choose to scale operation by adding or removing robots without disrupting any ongoing operations since the ACR systems require no structural changes to an existing facility.

That also means the systems are more affordable, especially for smaller businesses.

In Europe, many small-to-medium-sized enterprises see a need for automation, but their limited budget does not allow them to spend years implementing large projects. The ACRs turn out to be a fit in that case too.

ACR systems allow any business to start automation small, and grow as business grows. Many of its subscribers started to customize their solutions with a few robots and adding more when their demand expands.

4. Ideal for the age of e-commerce

In the age of e-commerce, businesses across the globe need to deal with flurries of online orders, which often come scattered and in large numbers. Plus the need to shorten delivery time to improve customer satisfaction, they need to significantly boost the order-fulfilment speed of their warehouses and DCs.

E-grocery emerges to be the channel embracing the growth capabilities. According to McKinsey, e-grocery channel grew by more than 50 percent in 2020 - compared to 2019 growth - for key European markets, creating an even stronger need for efficient e-grocery fulfillment solutions. Smaller unit picks, mixed orders, and a high speed of delivery make e-grocery labor intensive and therefore ideal for automation.

The ACR systems can boost order-fulfillment efficiency when handling large SKU portfolio as well as small orders with a high share of single-unit picks in e-grocery warehouses.

In several micro-fulfillment centers in Europe, the ACR systems have been implemented to handle home-delivery orders as well as click-and-collect orders with contactless deliveries over the counter at the storefront.

ABOUT HAI ROBOTICS

HAI ROBOTICS, the pioneer in Autonomous Case-handling Robot (ACR) systems, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse. The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.

Founded in 2016 in Shenzhen, China, HAI ROBOTICS has offices in the U.S., Europe, Japan, Southeast Asia, Australia, Hong Kong and Taiwan, serving customers from more than 30 countries and regions.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release

Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release

Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release

- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o

SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye